미국 · 보도자료 · NTRA · 2026-10-07 12:00
나테라, 흑색종 대상 Signatera 활용 무작위 임상 착수
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, an aggressive form of skin canc
